key: cord-0704344-4zkr4z0t authors: Zhou, Yusun; Han, Chunhua; Li, Hui; Zhou, Tingting; Geng, Chao; Luan, Xingwei; Feng, Xiaodong; Sui, Junna; Wang, Shuai; Yu, Teng; Xuan, Chao; Tian, Qingwu title: A rapid and highly effective approach for SARS‐CoV‐2 nucleic acid daily testing in more than four thousand single‐tube samples date: 2021-12-29 journal: J Clin Lab Anal DOI: 10.1002/jcla.24211 sha: fb3ef6e377e6bcd8410f8d41da1edd4df634b289 doc_id: 704344 cord_uid: 4zkr4z0t BACKGROUND: Presently, the global spread of COVID‐19 is still going on, with more than 0.6 million new cases confirmed per day (as of November 20, 2021). However, since China entered a post‐epidemic phase in mid‐March 2020, the daily number of new domestic infections in the Chinese mainland has been maintained at almost zero or single digits, which was attributed to a series of effective measures for COVID‐19 prevention and control adopted by the Chinese government. Among these measures, SARS‐CoV‐2 nucleic acid testing holds key role for the timely confirmation and isolation of the infections to prevent further transmission. METHODS: Referring to the national policy requirements, since April 30, 2020, The Affiliated Hospital of Qingdao University has conducted SARS‐CoV‐2 nucleic acid testing in its PCR laboratory for patients and social workers, as well as for environmental monitoring and employee screening. As of mid‐November 2020, the daily amount of single‐tube samples for nucleic acid testing rose above 4,000. RESULTS: In this article, a rapid and highly effective approach for SARS‐CoV‐2 nucleic acid daily testing is presented, allowing five technicians to complete nucleic acid testing in 6,500 single‐tube samples in one day with a high level of quality. Using this approach, since the samples entered the PCR laboratory, all testing results were reported in 2.5–3 h with satisfactory quality control and precise reporting criterion as prerequisites. CONCLUSION: This testing approach provides a referable workflow for other testing institutions and is expected to play an important role in COVID‐19 prevention and control. The novel coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the most severe health crisis worldwide in recent history. 1 According to the WHO COVID-19 dashboard, 2 as of November 20, 2021, 223 countries and regions reported more than 255 million confirmed cases, and more than 5.1 million patients died. And currently, the cases and deaths have been increasing continuously at the rate of over 0.6 million new cases and 6,000 deaths confirmed every day. 2 Fortunately, through painstaking efforts and tremendous sacrifices on prevention and control of the COVID-19 spread, China succeeded in turning the situation around. 3 On March 6, 2020, the daily increase in the number of domestic cases on the Chinese mainland dropped below 100 and fell further to a single digit on March 11. On March 18, 2020 , no new domestic cases were confirmed on the Chinese mainland for the first time since the beginning of the pandemic, and Wuhan lifted its 76-day outbound traffic restrictions on April 8. Since then, China's COVID-19 control has shifted its focus to preventing inbound cases and stemming domestic resurgence on an ongoing basis. In response to the evolving COVID-19 dynamics overseas, the Chinese government adopted a series of effective measures. SARS-CoV-2 nucleic acid testing, recommended as a standard confirmation protocol for SARS-CoV-2 infection by WHO, 4 plays a vital role in preventing the virus from entering China and stemming domestic case clusters. On April 10, 2020, through its joint prevention and control mechanism, the State Council informed that the PCR laboratory capacity of nucleic acid testing in medical institutions should be increased to ensure all those in need could be tested in a timely manner. 5 Subsequently, on April 18, the State Council explained the relevant requirements on registration and construction of testing laboratories, training and admittance for laboratory technicians, and quality control and bio-safety in laboratories. 6 Moreover, on April 30, the State Council emphasized that the capacity of nucleic acid testing in tertiary and county hospitals must be enhanced rapidly to ensure that the outpatients with fever, those highly suspected of COVID-19, and the admitted patients and their companions can be tested immediately. 7 To expand population coverage of SARS-CoV-2 nucleic acid testing and to ensure that persons returning to work and workers in key organizations could receive timely and periodic testing, testing capacity in secondary hospitals was required to be also strengthened and qualified social testing institutions were encouraged to provide testing services. 8 Furthermore, in June 2020, the State Council issued three bulletins, defining requirements on the quality and efficiency of SARS-CoV-2 nucleic acid testing, and urging continual technician training for nucleic acid testing to build a testing capacity reserve. 9-11 From July to December, the technical handbook for SARS-CoV-2 nucleic acid testing in medical institutions, 12,13 the guidelines on mixed-sample testing, 14 and the norms on 10-in-1 sampling 15 were sequentially released to ensure nucleic acid testing rightful operation and good quality. The Affiliated Hospital of Qingdao University, as a provincially regulated tertiary grade-A hospital, has conducted SARS-CoV-2 nucleic acid testing for outpatients with fever, those highly suspected of COVID-19, and admitted patients and their companions since April 30, 2020. To meet the demand for massive nucleic acid testing, our hospital constructed a specialized PCR laboratory with an area of 297 m 2 and appointed 10 fixed technicians to engage in nucleic acid testing (extraction and amplification). From June 22, 2020, all workers in our hospital began to be tested for nucleic acid screening (10-in-1 sampling for testing) once every 2 weeks. Our hospital also started to provide testing services for social workers on September 30, 2020. To further prevent potential nosocomial transmission of SARS-CoV-2, since November 16, 2020, the inpatients and their companions were required several times of nucleic acid testing, separately after admission, before discharge, and during hospitalization. In addition, environmental samples in key locations in our hospital were also sent to the PCR laboratory for nucleic acid testing to monitor the disinfection effect in air and on surfaces. As a result, as of mid-November 2020, the daily number of single-tube samples for nucleic acid testing reached above 4,000. With the increase in sample number, the ten technicians continually improved their workflow, and in early December 2020, a rapid and highly effective testing approach was established, allowing five technicians to complete 6,500 single-tube tests in one day with a high level of quality. This article describes the testing approach as a means to provide a referable workflow for other testing institutions. We also report our satisfactory quality control results and rightful reporting criterion. Outpatients with fever, those highly suspected of COVID-19, and admitted patients and their companions were separately guided to the appointed outdoor sampling sheds. The recommended nasopharyngeal swab was sampled. 12, 13 The inpatients in common and isolation wards were sampled in situ; the nasopharyngeal swab was also preferred. Companions of the inpatients in common wards were also sampled in situ. According to the stipulation released by our hospital, one patient was allowed to be taken care of by only one companion (no companions for inpatients in the isolation ward). Single testing was applied to all patients, and their companions, i.e., a single sample of each patient or companion was separately tested, and the samples of social workers and environments in key locations. The 10-in-1 testing method was applied to all workers in our hospital, in which ten nasopharyngeal swabs were mixed into one test tube, and sampling was performed in their attached departments. Two kinds of tubes were used for single (2 mL of preserving fluid in a 5-mL tube) and 10-in-1 (6 mL of preserving fluid in a 10-mL tube) testing. Guanidine salt and nano-silver were added the preserving fluid to inactivate the virus. For outpatients with fever and those highly suspected of COVID-19, another kind of tube containing a nucleic acid releasing agent in 500 μL of preserving fluid (Jianma Gene Technology Co., Ltd., Shandong, China) was used, and the sample in this kind of tube was directly submitted to nucleic acid amplification (dispensed with nucleic acid extraction). genes of the SARS-CoV-2 genome. The amplification procedure for the ORF1ab and N gene is presented in Table 1 . The RNase P gene was used as an internal standard for supervising virus sampling, sample loading, nucleic acid extraction, and amplification. Individual protection was performed according to the guidelines for preventing and controlling SARS-CoV-2 infections in medical institutions 17,18 and the guidelines on bio-safety in SARS-CoV-2 laboratories. 19 The sampling operators, sample receivers, and laboratory technicians who worked in the sample pretreatment zone followed senior secondary protection criteria, which includes an inner garment, surgical gown, medical protective mask and suit, disposable cap, eyes protector, latex gloves (duplex), and waterproof boot cover. The sample transporters and laboratory technicians who worked in the reagent preparation zone and nucleic acid amplification and analysis zone followed primary secondary protection criteria, including an inner garment or labor suit, surgical gown, medical protective mask, disposable cap, latex gloves, and shoe cover. In the PCR laboratory, daily disinfection was performed according to the technical handbook for SARS-CoV-2 nucleic acid testing in medical institutions. 12, 13 Briefly, at the end of daily testing, 2,000 mg/L (w/v) of chlorine disinfectant or 75% (v/v) of alcohol in water was used for disinfecting the worktable surface, laboratory ground, instruments, bio-safety cabinets, micropipettors, and the movable sample depository vehicles nearby each cabinet. If a sample spilled and polluted the operating bench, 5,500 mg/L (w/v) of chlorine disinfectant was used immediately. In addition, all medical waste derived from the PCR laboratory was transferred to a temporary storeroom and then centrally cleared out and destroyed by the appointed medical dustmen. The last technician to leave the PCR laboratory, after completing daily testing, turned on all ultraviolet lamps to disinfect the laboratory air for at least 2 h. Internal quality control (IQC) in the PCR laboratory was per- Figure 2B ), the ten technicians developed a rapid and highly effective testing approach. (a) The ten technicians divided themselves into two groups, with five technicians in each group. One group of five technicians worked for 3 days, and another five technicians worked for the next 3 days (the first five technicians rested during these 3 days); this scheme was then reiterated. (b) In each group, labor divisions were equally assigned to five technicians. As shown in Table 2 Table 3 , nucleic acid extraction was carried out in the sequence of Stream SP96 1-7. Based on the time consumption difference in SARS-CoV-2 nucleic acid amplification, the two kinds of PCR amplification instruments were used in a reasonable arrangement as shown in Table 3 . Due to the rapid and highly effective approach, all testing results were reported in 2.5-3 h since the samples were received by the PCR laboratory, which was compliant with the requirements regarding the reporting time limit in the technical handbook for SARS-CoV-2 nucleic acid testing. 12, 13 In addition, in this testing approach, technician composition and labor division were both flexible, which meant that some of the ten technicians could withdraw from the PCR laboratory if the sample amount declined abruptly (e.g., the daily sample number for single testing decreased from 3,500-plus to fewer than 2,000 in early May 2021 due to policy changes on COVID-19 prevention in our hospital) and then the labor divisions would be redefined and recombined. The RNase P gene was used as an internal standard for supervising the entire operating procedure for each sample, including virus sampling, sample loading, nucleic acid extraction, and amplification. Therefore, all testing results were reported with amplification of the RNase P gene as a prerequisite. Furthermore, the daily IQC required that the two positive controls with low concentrations (approximate 500 and 1,000 copies/mL) of SARS-CoV-2 nucleic acid were visibly amplified, and the three negative controls had no amplification (Figure 3 ). The physiological-saline-diluted positive control with four concentration levels (approximately 25, 50, 100, 200 copies/mL) was used to investigate the testing procedure's analytical sensitivity from sample loading to nucleic acid amplification. The four concentrations of the ORF1ab and N genes all had distinct amplification ( Figure 3) , which confirmed the effectiveness and sensitivity of the used reagents and the procedure's operations, with a detection limit (<25 copies/mL) similar to or even lower than most reports on coronavirus nucleic acid testing. 20,21 Interestingly, by comparing the amplification curves (Figure 3 ) of the ORF1ab gene with those of the N gene at the same concentration level, we found that the selected amplified fragment by DA0992 16 in the N gene sequence had a higher amplification efficiency and a lower cycle threshold (Ct) value, which might be attributed to a higher AT content in this selected fragment. In addition, although the two kinds of PCR amplification instruments were both satisfactory for detecting a low concentration of the two target genes, compared with AppliedBiosystems ® 7500, LightCycler ® 480 II exhibited higher detection sensitivity (Figure 3 ), indicating its lower detection limit. In the other two time periods, only three or four technicians were assigned (Table 2) . Finally, to provide enough resting time for the five technicians after laborious work, another group of five technicians took over testing work, and the first five technicians rested for several days. After soliciting individual opinions, an interval of 3 days was thought to be beneficial to refresh the workers' energy. Although the laboratory configurations in other testing institutions are different from each other, the testing approach presented in this article can provide a referable workflow and be adapted for a suitable number of technicians and a reasonable daily working profile. Depending on the developed testing approach, a short turnaround time of 2.5-3 h was achieved since samples were received by the PCR laboratory, which was much lower than the official requirement (6-24 h). 12, 13 The satisfactory results of daily quality control and high sensitivity of the detection method ( Figure 3 ) proved that the testing approach was reliable and effective. Furthermore, the testing results were reported referring to the latest national reporting criterion, 23 which ensured that the testing reporting was lawful and rightful, embodying the responsibility of medical workers for the tested population. In addition, individual protection and daily disinfection were performed according to the national operation standard, [17] [18] [19] which protected the personal safety of the technicians and prevented residual nucleic acid from polluting the laboratory. In summary, these strategies ensured that our testing approach ran confidently and successfully, and contributed a positive feedforward to national COVID-19 prevention and control. Up to now, there has been an article to report their workflow in the PCR laboratory for large-scale population screening for SARS-CoV-2 infection. 27 In the article, the authors described their laboratory configuration and technicians' labor divisions ( expected to play an important role in COVID-19 prevention and control. The authors sincerely thank the sampling operators, sample receivers, and other appointed medical workers for their contributions to our hospital's COVID-19 prevention and control. We thank LetPub (www.letpub.com) for linguistic assistance and pre-submission expert review. The authors declare that they have no competing interests. All the data related to this work are available from the corresponding author upon reasonable request. Yusun Zhou https://orcid.org/0000-0001-8618-3853 Characteristics of SARS-CoV-2 and COVID-19 World Health Organization WHO coronavirus disease (COVID-19) dashboard [Updating State Council Information Office of the People's Republic of China. Fighting COVID-19: China in action Diagnostic testing for SARS-CoV-2 Epidemic Prevention and Control Mechanism of the State Council. An announcement on boosting the capacity of COVID-19 prevention and treatment in medical institutions Epidemic Prevention and Control Mechanism of the State Council. A notification on promoting national capacity of SARS-CoV-2 testing Epidemic Prevention and Control Mechanism of the State Council. A notice on further enhancing COVID-19 prevention and control in medical institutions Epidemic Prevention and Control Mechanism of the State Council. Guidelines on conducting nationwide COVID-19 prevention and control on an ongoing basis Epidemic Prevention and Control Mechanism of the State Council. A notification on maintaining quality control for SARS-CoV-2 nucleic acid testing Epidemic Prevention and Control Mechanism of the State Council. Measures on accelerating nationwide SARS-CoV-2 nucleic acid testing Epidemic Prevention and Control Mechanism of the State Council. A notice on further advancing the capacity of SARS-CoV-2 nucleic acid testing in medical institutions /5b559 7bcbf fc462 3b0b9 ec051 a0f17 3d.shtml Epidemic Prevention and Control Mechanism of the State Council. Technical handbook for SARS-CoV-2 nucleic acid testing in medical institutions (Trial Version 1) Epidemic Prevention and Control Mechanism of the State Council. Technical handbook for SARS-CoV-2 nucleic acid testing in medical institutions (Trial Version 2) Epidemic Prevention and Control Mechanism of the State Council. Technical guidelines on SARS-CoV-2 nucleic acid testing in mixed samples Technical norms on 10-in-1 sampling for SARS-CoV-2 nucleic acid testing of Sun Yat-sen University. DA0992: A rapid nucleic acid detection kit for 2019-nCoV (PCR-fluorescence) National Health Commission of the People's Republic of China. Guidance for preventing and controlling SARS-CoV-2 infections in medical institutions National Health Commission of the People's Republic of China Guidance for preventing and controlling SARS-CoV-2 infections in medical institutions National Health Commission of the People's Republic of China. Guidelines on bio-safety in SARS-CoV-2 laboratories Recent advances and perspectives of nucleic acid detection for coronavirus Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures Rapid response to an outbreak in Qingdao, China Epidemic Prevention and Control Mechanism of the State Council Protocol on COVID-19 prevention and control Reemergent cases of COVID-19-Xinfadi wholesales market COVID-19 outbreak caused by contaminated packaging of imported cold-chain products-Liaoning Province, China Genome characterization of the first outbreak of COVID-19 delta variant B.1.617.2-Guangzhou City Laboratory management for largescale population screening for SARS-CoV-2 Epidemic Prevention and Control Mechanism of the State Council Guidelines on conducting large-scale testing of SARS-CoV-2 nucleic acid in population Epidemic Prevention and Control Mechanism of the State Council Guidelines on conducting large-scale testing of SARS-CoV-2 nucleic acid in population